Search hospitals > North Carolina > Durham
Duke Eye Center
Claim this profileDurham, North Carolina 27701
Global Leader in Age-Related Macular Degeneration
Global Leader in Glaucoma
Conducts research for Retinal Disease
Conducts research for Macular Edema
Conducts research for Retinitis
108 reported clinical trials
15 medical researchers
Summary
Duke Eye Center is a medical facility located in Durham, North Carolina. This center is recognized for care of Age-Related Macular Degeneration, Glaucoma, Retinal Disease, Macular Edema, Retinitis and other specialties. Duke Eye Center is involved with conducting 108 clinical trials across 106 conditions. There are 15 research doctors associated with this hospital, such as Lejla Vajzovic, MD, Sharon F Freedman, MD, Cynthia A Toth, MD, and Mays Dairi, MD.Area of expertise
1Age-Related Macular Degeneration
Global LeaderStage I
Stage II
CFI rare variant positive
2Glaucoma
Global LeaderTop PIs
Lejla Vajzovic, MDDuke Eye Center1 year of reported clinical research
Studies Retinal Disease
Studies Retinopathy of Prematurity
7 reported clinical trials
8 drugs studied
Sharon F Freedman, MDDuke University Eye Center2 years of reported clinical research
Studies Retinal Disease
Studies Premature Birth
5 reported clinical trials
5 drugs studied
Cynthia A Toth, MDDuke University Eye Center7 years of reported clinical research
Studies Retinal Disease
Studies Retinopathy of Prematurity
4 reported clinical trials
5 drugs studied
Mays Dairi, MDDuke University Eye Center1 year of reported clinical research
Studies Nervous System Disorders
Studies Optic Neuropathy
2 reported clinical trials
1 drug studied
Clinical Trials running at Duke Eye Center
Age-Related Macular Degeneration
Retinal Detachment
Glaucoma
Retinal Disease
Premature Birth
Retinopathy of Prematurity
Diabetic Retinopathy
Macular Edema
Convergence Insufficiency
Retinal Dystrophy
RGX-314 Gene Therapy
for Age-Related Macular Degeneration
RGX-314 is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD). Wet AMD is characterized by loss of vision due to new, leaky blood vessel formation in the retina. Wet AMD is a significant cause of vision loss in the United States, Europe and Japan, with up to 2 million people living with wet AMD in these geographies alone. Current anti-VEGF therapies have significantly changed the landscape for treatment of wet AMD, becoming the standard of care due to their ability to prevent progression of vision loss in the majority of patients. These therapies, however, require life-long intraocular injections, typically repeated every four to 12 weeks in frequency, to maintain efficacy. Due to the burden of treatment, patients often experience a decline in vision with reduced frequency of treatment over time. RGX-314 is being developed as a potential one-time treatment for wet AMD.
Recruiting2 awards Phase 32 criteria
Photobiomodulation
for Age-Related Macular Degeneration
This study is an open-label, prospective, multi-center extension study on the continued use of photobiomodulation (PBM) in subjects with dry age-related macular degeneration (AMD) that participated in the CSP005 LIGHTSITE III study.
Recruiting1 award Phase 2 & 3
OCU410
for Age-Related Macular Degeneration
This is a Phase 1/2 Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration (AMD). This is a multicenter study, which will be conducted in two phases and will enroll up to a total of 63 subjects.
Recruiting1 award Phase 1 & 27 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Duke Eye Center?
Duke Eye Center is a medical facility located in Durham, North Carolina. This center is recognized for care of Age-Related Macular Degeneration, Glaucoma, Retinal Disease, Macular Edema, Retinitis and other specialties. Duke Eye Center is involved with conducting 108 clinical trials across 106 conditions. There are 15 research doctors associated with this hospital, such as Lejla Vajzovic, MD, Sharon F Freedman, MD, Cynthia A Toth, MD, and Mays Dairi, MD.